Clinical vertebral fractures · postmenopausal women at lower risk of fractures1
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Wrist fractures · pPostmenopausal women at higher risk of fractures1
It is very uncertain whether risedronate 5 mg/day changes wrist fractures compared with placebo (very low certainty).
1 finding from 1 review
RR 0.64 [0.33, 1.24]
Studies not reported
Very low
Withdrawals due to adverse events · pPostmenopausal women at higher risk of fractures1
Risedronate 5 mg/day showed no clear difference in withdrawals due to adverse events compared with placebo (high certainty).
1 finding from 1 review
RR 0.98 [0.9, 1.07]
Studies not reported
High
Serious adverse events · pPostmenopausal women at higher risk of fractures1
Risedronate 5 mg/day showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
RR 1 [0.94, 1.07]
Studies not reported
Moderate
Non‐vertebral fractures · postmenopausal women at lower risk of fractures1
It is very uncertain whether risedronate 5 mg/day changes non‐vertebral fractures compared with placebo (very low certainty).
1 finding from 1 review
RR 0.54 [0.22, 1.35]
Studies not reported
Very low
Hip Fracture · postmenopausal women at lower risk of fractures1
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Wrist fractures · postmenopausal women at lower risk of fractures1
Risedronate 5 mg/day showed no clear difference in wrist fractures compared with placebo (low certainty).
1 finding from 1 review
RR 0.48 [0.03, 7.5]
Studies not reported
Low
Withdrawals due to adverse events · postmenopausal women at lower risk of fractures1
Risedronate 5 mg/day showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
RR 0.67 [0.38, 1.18]
Studies not reported
Low
Serious adverse events · postmenopausal women at lower risk of fractures1
It is very uncertain whether risedronate 5 mg/day changes serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
RR 0.74 [0.42, 1.3]
Studies not reported
Very low
Clinical vertebral fractures · pPostmenopausal women at higher risk of fractures1
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Non‐vertebral fractures · pPostmenopausal women at higher risk of fractures1
Risedronate 5 mg/day probably leads to lower non‐vertebral fractures compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.8 [0.72, 0.9]
Studies not reported
Moderate
Hip Fracture · pPostmenopausal women at higher risk of fractures1
Risedronate 5 mg/day may leads to lower hip fractures compared with placebo (low certainty).
1 finding from 1 review
RR 0.73 [0.56, 0.94]
Studies not reported
Low
Incidence of PEa (early postoperative period) · people undergoing surgery or at risk of developing VTE because of surgery, trauma or ICU stay
IPC plus pharmacological prophylaxis may leads to lower incidence of PEa (early postoperative period) compared with IPC alone (low certainty).
1 finding from 1 review
Incidence of DVTc (early postoperative period) · people undergoing surgery or at risk of developing VTE because of surgery, trauma or ICU stay
IPC plus pharmacological prophylaxis may leads to lower incidence of DVTc (early postoperative period) compared with IPC alone (low certainty).
1 finding from 1 review
Incidence of bleedingd (early postoperative period) · people undergoing surgery or at risk of developing VTE because of surgery, trauma or ICU stay
It is very uncertain whether IPC plus pharmacological prophylaxis changes incidence of bleedingd (early postoperative period) compared with IPC alone (very low certainty).
1 finding from 1 review
Incidence of major bleedingf (early postoperative period) · people undergoing surgery or at risk of developing VTE because of surgery, trauma or ICU stay
It is very uncertain whether IPC plus pharmacological prophylaxis changes incidence of major bleedingf (early postoperative period) compared with IPC alone (very low certainty).
1 finding from 1 review
Incidence of PEa (early postoperative period) · people undergoing surgery or at risk of developing VTE because of surgery, trauma or ICU stay
IPC plus pharmacological prophylaxis may leads to lower incidence of PEa (early postoperative period) compared with pharmacological prophylaxis alone (low certainty).
1 finding from 1 review
Incidence of DVTc (early postoperative period) · people undergoing surgery or at risk of developing VTE because of surgery, trauma or ICU stay
IPC plus pharmacological prophylaxis leads to lower incidence of DVTc (early postoperative period) compared with pharmacological prophylaxis alone (high certainty).
1 finding from 1 review
Incidence of bleedingd (early postoperative period) · people undergoing surgery or at risk of developing VTE because of surgery, trauma or ICU stay
It is very uncertain whether IPC plus pharmacological prophylaxis changes incidence of bleedinge (early postoperative period) compared with pharmacological prophylaxis alone (very low certainty).
1 finding from 1 review
Incidence of major bleedingg (early postoperative period) · people undergoing surgery or at risk of developing VTE because of surgery, trauma or ICU stay
It is very uncertain whether IPC plus pharmacological prophylaxis changes incidence of major bleedingg (early postoperative period) compared with pharmacological prophylaxis alone (very low certainty).
1 finding from 1 review